12/20/2022 8:08:21 AM
MAIA Holds Successful Pre-IND Meeting With FDA For US Expansion Of THIO-101 Phase 2 Trial For Non-Small Cell Lung Cancer
8/22/2022 8:11:19 AM
MAIA Biotechnology Q2 Net Loss $3.3 Mln Vs Net Loss Of About $3.5 Mln Prior Year
8/2/2022 8:07:29 AM
MAIA Biotechnology Gets FDA Orphan Drug Designation For THIO For Treatment Of Small-Cell Lung Cancer